Huazhong University of Science and Technology
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing for the treatment of cancer
Company stage: Clinical
Diseases: T- and B-cell malignancies
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai and Nanjing, China
Shanghai IASO Biotechnology develops next generation allogeneic CAR-T cell therapies and uses CRISPR to make the CAR-T cells fratricide-resistent. The company is currently developing multiple pre-clinical programmes using CRISPR, to treat T- and B-cell malignancies.